Trilaciclib+mFOLFIRINOX Clinical Trials

1 actively recruiting trial

Also known as: CDK 4/6 inhibitor, G1T28

Pipeline

Phase 2: 1

Top Sponsors

The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School1

Indications

Pancreatic Cancer1
Cancer1

Other1 trial

A Study of Trilaciclib Combined With mFOLFIRINOX in the Treatment of Patients With Advanced Pancreatic Cancer

Phase 2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.